Picture of 4D Molecular Therapeutics logo

FDMT — 4D Molecular Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapSucker Stock

Momentum

Relative Strength (%)
1m-33.9%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-59.19%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of 4D Molecular Therapeutics EPS forecast chart

Profile Summary

4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector), and pulmonology (aerosol vector). The Company's product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
March 11th, 2015
Public Since
January 1st, 1970
No. of Shareholders
96
No. of Employees
121
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
32,138,814

FDMT Share Price Performance

Latest News for FDMT

Upcoming Events for FDMT

4D Molecular Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference

Q4 2021 4D Molecular Therapeutics Inc Earnings Release

Q1 2022 4D Molecular Therapeutics Inc Earnings Release

Similar to FDMT

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

Achilles Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email